Polygenic Hazard Scores in Preclinical Alzheimer Disease

Overview

Journal Ann Neurol

Specialty Neurology

Date 2017 Sep 24

PMID 28940650

Citations 36

Authors

Chin Hong Tan

Bradley T Hyman

Jacinth J X Tan

Christopher P Hess

William P Dillon

Gerard D Schellenberg

Lilah M Besser

Walter A Kukull

Karolina Kauppi

Linda K McEvoy

Ole A Andreassen

Anders M Dale

Chun Chieh Fan

Rahul S Desikan

Affiliations

Soon will be listed here.

Abstract

Identifying asymptomatic older individuals at elevated risk for developing Alzheimer disease (AD) is of clinical importance. Among 1,081 asymptomatic older adults, a recently validated polygenic hazard score (PHS) significantly predicted time to AD dementia and steeper longitudinal cognitive decline, even after controlling for APOE ɛ4 carrier status. Older individuals in the highest PHS percentiles showed the highest AD incidence rates. PHS predicted longitudinal clinical decline among older individuals with moderate to high Consortium to Establish a Registry for Alzheimer's Disease (amyloid) and Braak (tau) scores at autopsy, even among APOE ɛ4 noncarriers. Beyond APOE, PHS may help identify asymptomatic individuals at highest risk for developing Alzheimer neurodegeneration. Ann Neurol 2017;82:484-488.

Citing Articles

Somatic and Stem Cell Bank to Study the Contribution of African Ancestry to Dementia: African iPSC Initiative.

Maina M, Isah M, Marsh J, Muhammad Z, Babazau L, Idris A medRxiv. 2025; .

PMID: 39974113 PMC: 11838935. DOI: 10.1101/2025.01.24.25320911.

Breastfeeding, genetic susceptibility, and the risk of asthma and allergic diseases in children and adolescents: a retrospective national population-based cohort study.

Hou W, Guan F, Chen W, Qi J, Huang S, Zeng P BMC Public Health. 2024; 24(1):3056.

PMID: 39501212 PMC: 11539314. DOI: 10.1186/s12889-024-20501-0.

Association between probable sarcopenia and dementia risk: a prospective cohort study with mediation analysis.

Ling Y, Yuan S, Huang X, Tan S, Cheng H, Li L Transl Psychiatry. 2024; 14(1):398.

PMID: 39353910 PMC: 11445531. DOI: 10.1038/s41398-024-03131-3.

Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults.

Soldan A, Wang J, Pettigrew C, Davatzikos C, Erus G, Hohman T Brain Commun. 2024; 6(5):fcae276.

PMID: 39229494 PMC: 11369827. DOI: 10.1093/braincomms/fcae276.

Emerging Microglial Therapies and Targets in Clinical Trial.

Ling Y, Crotti A Adv Neurobiol. 2024; 37:623-637.

PMID: 39207717 DOI: 10.1007/978-3-031-55529-9_35.

References

Marioni R, Campbell A, Hagenaars S, Nagy R, Amador C, Hayward C . Genetic Stratification to Identify Risk Groups for Alzheimer's Disease. J Alzheimers Dis. 2017; 57(1):275-283. PMC: 5345653. DOI: 10.3233/JAD-161070. View

Sabuncu M, Buckner R, Smoller J, Lee P, Fischl B, Sperling R . The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex. 2011; 22(11):2653-61. PMC: 3464416. DOI: 10.1093/cercor/bhr348. View

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

Brookmeyer R, Gray S, Kawas C . Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998; 88(9):1337-42. PMC: 1509089. DOI: 10.2105/ajph.88.9.1337. View

Qian J, Wolters F, Beiser A, Haan M, Ikram M, Karlawish J . APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med. 2017; 14(3):e1002254. PMC: 5360223. DOI: 10.1371/journal.pmed.1002254. View

Desikan R, Fan C, Wang Y, Schork A, Cabral H, Cupples L . Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Med. 2017; 14(3):e1002258. PMC: 5360219. DOI: 10.1371/journal.pmed.1002258. View

Caselli R, Reiman E, Locke D, Hutton M, Hentz J, Hoffman-Snyder C . Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007; 64(9):1306-11. DOI: 10.1001/archneur.64.9.1306. View

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

Dubois B, Hampel H, Feldman H, Scheltens P, Aisen P, Andrieu S . Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12(3):292-323. PMC: 6417794. DOI: 10.1016/j.jalz.2016.02.002. View

10.

Bonham L, Geier E, Fan C, Leong J, Besser L, Kukull W . Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol. 2016; 3(9):668-77. PMC: 5018579. DOI: 10.1002/acn3.333. View

11.

Shepherd B . The cost of checking proportional hazards. Stat Med. 2007; 27(8):1248-60. DOI: 10.1002/sim.3020. View

12.

Beekly D, Ramos E, Lee W, Deitrich W, Jacka M, Wu J . The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007; 21(3):249-58. DOI: 10.1097/WAD.0b013e318142774e. View

13.

Bu G . Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009; 10(5):333-44. PMC: 2908393. DOI: 10.1038/nrn2620. View

14.

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

15.

Harrison T, Mahmood Z, Lau E, Karacozoff A, Burggren A, Small G . An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults. eNeuro. 2016; 3(3). PMC: 4945997. DOI: 10.1523/ENEURO.0098-16.2016. View